Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy

NCT ID: NCT00464880

Last Updated: 2007-11-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-09-30
• Study Completion Date: 2007-11-30

Brief Summary

This study will assess the reno-protective effect of renin inhibition with aliskiren as an alternative to irbesartan in type 2 diabetes patients with incipient/overt diabetic nephropathy.

Detailed Description

Antiproteinuric Effects of Aliskiren (Renin Inhibitor), Irbesartan (Angiotensin Receptor Antagonist) and the Combination in Hypertensive Patients With Type 2 Diabetes and Incipient/Overt Diabetic Nephropathy

Conditions

Diabetes Type 2

Keywords

Placebo-controlled study; assess the renoprotective effect of renin inhibition; Aliskiren as an alternative to irbesartan; Type 2 diabetes patients; incipient/overt diabetic nephropathy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

Aliskiren

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male and/or female subjects between the ages of 30-80 years with a diagnosis of type 2 diabetes (World Health Organization criteria)
• Body mass index (BMI) within the range of 20 and 32.
• Incipient or overt diabetic nephropathy (urinary albumin excretion ≥ 100 but ≤ 2000 mg/day).
• Glomerular filtration rate (GFR) ≥ 40 ml/min documented in the last 4 months prior to randomization
• To be eligible for randomization, patients must fulfill the following criteria:

1. Patients on ongoing hypertensive therapy must have a blood pressure ≥ 135/85 mmHg but lower than 170/105 mmHg at Visit 2 (Day -1) AND patients must be on stable antihypertensive medications for at least 8 weeks prior to Visit 2 (run-in period).

2. Newly diagnosed hypertensive patients must have a blood pressure ≥ 135/85 mmHg but lower than 170/105 mmHg at Visit 2 (Day -1).

• Patients must be on stable hypoglycemic medications for at least 8 weeks prior to Visit 2 (Day -1).
• Patients must be willing and medically able to discontinue all angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), aldosterone receptor antagonist and potassium sparing diuretic medications for the duration of the study.
• Female patients must be postmenopausal, have had a bilateral oophorectomy, or have been surgically sterilized or hysterectomized at least 6 months prior to screening.
• Oral body temperature within the range of 35.0-37.5 °C
• Able to provide written informed consent prior to study participation.
• Able to communicate well with the investigator and comply with the requirements of the study.

Exclusion Criteria

• Severe hypertension, Grade 3 World Health Organization (WHO) classification (mean sitting diastolic blood pressure [MSDBP] ≥ 110 mmHg and/or mean sitting systolic blood pressure [MSSBP] ≤ 180 mmHg)
• Acetylsalicylic acid (ASA) treatment > 1 g/day or regular use of nonsteroidal anti-inflammatory drugs (NSAIDs)
• Kidney disease not caused by diabetes or hypertension
• Serum potassium < 3.5 or > 5.1 mEq/L
• GFR < 40 ml/min/1.73m2 as measured by the Modification of Diet in Renal Disease (MDRD) formula
• Serum albumin < 2.0 mg/dL
• History of hypertensive encephalopathy or cerebrovascular accident in the last 12 months prior to Visit 1
• Transient ischemic cerebral attack during the 6 months prior to Visit 1
• Current diagnosis of heart failure (New York Heart Association [NYHA] Class II-IV)
• History of myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention (PCI) during the 6 months prior to Visit 1
• Second or third degree heart block without a pacemaker
• Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia
• Clinically significant valvular heart disease
• Type 1 diabetes mellitus
• Uncontrolled type II diabetes mellitus; hemoglobin subtype A1C (HbA1C) > 11%
• History of malignancy including leukemia and lymphoma (but not basal cell skin carcinoma) within the past five years
• Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.
• Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.
• Significant illness within the two weeks prior to dosing.
• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs including, but not limited to, any of the following:

• History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection
• Currently active or previously active inflammatory bowel disease during the 12 months prior to Visit 1
• Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months prior to Visit 1.
• Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase
• Evidence of hepatic disease, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portacaval shunt
• Current treatment with cholestyramine or colestipol resins
• History of immunocompromise, including a positive test result.
• History of a positive hepatitis B surface antigen (HBsAg) or hepatitis C test result.
• History of drug or alcohol abuse within the 12 months prior to dosing.
• Persons directly involved in the execution of this protocol.
• Any condition that, in the opinion of the investigator or the Novartis medical monitor, would jeopardize the evaluation of efficacy or safety
• History of noncompliance to medical regimens or unwillingness to comply with the study protocol
• Known or suspected contraindications to the study medications, including history of allergy to ACE inhibitors and/or to thiazide diuretics or other sulfonamide derived drug
• Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study
• Use of any prescription drug or over-the-counter (OTC) medication which is prohibited by the protocol.
• Patients who previously participated in any aliskiren study.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: lead

Principal Investigators

Novartis

Role: PRINCIPAL_INVESTIGATOR

Investigative site

Locations

Novartis

Gentofte Municipality, , Denmark

Countries

Denmark

References

Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E, Parving HH. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care. 2009 Oct;32(10):1873-9. doi: 10.2337/dc09-0168. Epub 2009 Jul 8.

Reference Type: DERIVED

PMID: 19587362 (View on PubMed)

Other Identifiers

CSPP100A2243

Identifier Type: -

Identifier Source: org_study_id